172 related articles for article (PubMed ID: 36170624)
1. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.
Cailleux F; Agostinetto E; Lambertini M; Rothé F; Wu HT; Balcioglu M; Kalashnikova E; Vincent D; Viglietti G; Gombos A; Papagiannis A; Veys I; Awada A; Sethi H; Aleshin A; Larsimont D; Sotiriou C; Venet D; Ignatiadis M
JCO Precis Oncol; 2022 Sep; 6():e2200148. PubMed ID: 36170624
[TBL] [Abstract][Full Text] [Related]
2. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
Garcia-Murillas I; Chopra N; Comino-Méndez I; Beaney M; Tovey H; Cutts RJ; Swift C; Kriplani D; Afentakis M; Hrebien S; Walsh-Crestani G; Barry P; Johnston SRD; Ring A; Bliss J; Russell S; Evans A; Skene A; Wheatley D; Dowsett M; Smith IE; Turner NC
JAMA Oncol; 2019 Oct; 5(10):1473-1478. PubMed ID: 31369045
[TBL] [Abstract][Full Text] [Related]
5. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
[TBL] [Abstract][Full Text] [Related]
8. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Lipsyc-Sharf M; de Bruin EC; Santos K; McEwen R; Stetson D; Patel A; Kirkner GJ; Hughes ME; Tolaney SM; Partridge AH; Krop IE; Knape C; Feger U; Marsico G; Howarth K; Winer EP; Lin NU; Parsons HA
J Clin Oncol; 2022 Aug; 40(22):2408-2419. PubMed ID: 35658506
[TBL] [Abstract][Full Text] [Related]
10. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
13. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
Shaw JA; Page K; Wren E; de Bruin EC; Kalashnikova E; Hastings R; McEwen R; Zhang E; Wadsley M; Acheampong E; Renner D; Gleason KLT; Ambasager B; Stetson D; Fernandez-Garcia D; Guttery D; Allsopp RC; Rodriguez A; Zimmermann B; Sethi H; Aleshin A; Liu MC; Richards C; Stebbing J; Ali S; Rehman F; Cleator S; Kenny L; Ahmed S; Armstrong AC; Coombes RC
JCO Precis Oncol; 2024 Apr; 8():e2300456. PubMed ID: 38691816
[TBL] [Abstract][Full Text] [Related]
14. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
15. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Hou JY; Chapman JS; Kalashnikova E; Pierson W; Smith-McCune K; Pineda G; Vattakalam RM; Ross A; Mills M; Suarez CJ; Davis T; Edwards R; Boisen M; Sawyer S; Wu HT; Dashner S; Aushev VN; George GV; Malhotra M; Zimmermann B; Sethi H; ElNaggar AC; Aleshin A; Ford JM
Gynecol Oncol; 2022 Nov; 167(2):334-341. PubMed ID: 36117009
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM; Brown Swigart L; Ahmed Z; Sayaman RW; Renner D; Kalashnikova E; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Asare S; Liu MC; Albain K; Chien AJ; Forero-Torres A; Isaacs C; Nanda R; Tripathy D; Rodriguez A; Sethi H; Aleshin A; Rabinowitz M; Perlmutter J; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Cancer Cell; 2023 Jun; 41(6):1091-1102.e4. PubMed ID: 37146605
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
[TBL] [Abstract][Full Text] [Related]
20. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
Nel I; Herzog H; Aktas B
Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
